1xbet모바일., Ltd.

Pharmaceuticals
September 25, 2018

1xbet모바일

  • Busulfex is used around the world as a pretreatment prior to hematopoietic stem cell transplantation in patients with hematologic cancers

  • The approval in Japan reflects the once-daily usage pattern 1xbet모바일 Busulfex in adults in other countries

  • The addition of a once-daily dosage regimen is expected to reduce the burdens and risks 1xbet모바일 patients and medical staff

1xbet모바일., Ltd. today announces it has received regulatory approval for a once-daily form of Busulfex®Injection 60 mg (generic name is busulfan). Busulfex is a conditioning regimen administered via intravenous drip to patients prior to undergoing hematopoietic stem cell transplantation.